Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Esoferr powder for injection

Ferron Par Pharmaceuticals

Ingredients in every vial

Esomeprazole 40 mg

Each package contains

1 vial of 40 mg

Dosage form

Powder for injection

Dosage formPowder for injection

Flavour

None

W.H.O. classification

A02A
A02A

A.T.C. Level 1

Anatomical Main group

A - Alimentary tract and metabolism
A02A

A.T.C. Level 2

Therapeutic subgroup

A02 - Drugs for Acid Related Disorders
A02A

A.T.C. Level 3

Pharmacological subgroup

A02A - Antacids

Available in

Indonesia

Warnings

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CAUTIONThis item may not be safe for use while operating heavy machinery. Use with caution and after consultation with your doctor.

Pregnancy

CAUTIONThis item may not be safe for use during pregnancy. Use with caution and after consultation with your doctor.

Lactation

NOT RECOMMENDEDThis item is not safe for use during lactation.

Indication

Esomeprazole injection is indicated for gastric antisecretory treatment when the oral route is not possible, such as:
Gastroesophageal reflux disease
in patients with esophagitis and/or severe symptoms of reflux.
Healing of gastric ulcers
associated with NSAIDs therapy.
Short-term maintenance of hemostasis and prevention of rebleeding
in patients following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers.

Dosage

18 YEARS OLD AND ABOVE
• Gastric antisecretory treatment when the oral route is not possible:
– Patients who cannot take oral medicines may be treated parenterally with 20-40 mg once daily. Patients with reflux esophagitis should be treated with 40 mg once daily. Patients with symptomatically for reflux disease should be treated with 20 mg once daily.
– For healing of gastric ulcers associated with NSAID therapy the usual dose is 20 mg once daily.
Usually the IV treatment durations short and transfer to oral treatment should be made as soon as possible.


• Maintenance of hemostasis and prevention of rebleeding of gastric and duodenal ulcers following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers:
80 mg should be administered as a bolus infusion over 30 minutes, followed by continuous intravenous infusion of 8 mg/hour given over 3 days (72 hours)

The parenteral treatment period should be followed by acid-suppression therapy with esomeprazole 40 mg gastro-resistant tablet once daily for 4 weeks

0 TO 18 YEARS OLD
Esomeprazole IV should not be used in children and adolescent since no data is available.

IMPAIRED HEPATIC FUNCTION
Treatment for bleeding ulcer patients with severe liver impairment, following an initial bolus dose of 80 mg esomeprazole for infusion, a continuous intravenous infusion dose of 4 mg/hour for 71.5 hours may be sufficient.